10x Genomics Acquires Scale Biosciences, Bolstering Single-Cell Analysis Capabilities

10x Genomics, a leader in single-cell and spatial genomics technologies, has announced the acquisition of Scale Biosciences, a move set to enhance its capabilities in single-cell analysis. The deal, valued at $30 million in upfront cash and stock plus undisclosed milestone payments, brings Scale's innovative Quantum Barcoding technology under the 10x Genomics umbrella.

Acquisition Details and Strategic Implications

Scale Biosciences, a recent Fierce Medtech Fierce 15 winner, has developed a massively parallel tagging technology called Quantum Barcoding. This technology allows researchers to pool samples during processing while maintaining individual transcript labeling within cells. Using a 96-well plate containing thousands of microwells, the approach enables the sequencing of millions of cells simultaneously without requiring additional specialized equipment.

Serge Saxonov, CEO of 10x Genomics, emphasized the strategic importance of the acquisition, stating, "This acquisition is a step towards that vision—reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale's inventions with 10x's global platform and innovation engine, we will broaden the capabilities and reach of existing and future products."

As part of the deal, Scale's scientific co-founders, including Garry Nolan, Ph.D., from Stanford University, Jay Shendure, M.D., Ph.D., and Cole Trapnell, Ph.D., from the University of Washington, and the company's chief scientific officer, Frank Steemers, Ph.D., will join 10x Genomics as advisors.

Product Integration and Research Initiatives

10x Genomics plans to implement Scale's single-cell profiling solutions within its Chromium platform. Key Scale products will remain on the market, and the company will continue its participation in research programs such as the 100 Million Cell Challenge and the Billion Cells Project through the Chan Zuckerberg Initiative.

Earlier this year, Scale began shipping its RNA analysis kits, which aim to cost less than one cent per cell. In 2024, the company partnered with Revvity's BioLegend business to launch a single-cell protein solution for identifying rare cell subtypes.

Financial Performance and Industry Outlook

Alongside the acquisition announcement, 10x Genomics released its second-quarter earnings report. The company reported total revenue of $172.9 million, which includes $27.3 million received through a patent litigation settlement with Bruker. Excluding this settlement, sales amounted to $145.6 million, representing a 5% decrease compared to the same period in 2024. Despite this, the company achieved a net income of $34.5 million, a significant improvement from the $37.9 million net loss reported last year.

Saxonov acknowledged the current market challenges, stating, "Amid continued uncertainty in the funding environment, we're encouraged by the resilience of our business and the dedication of our team. We're focused on disciplined execution, and remain confident in the strength of our technology, the momentum behind our platforms and the significant long-term opportunity in front of us."